Drug combo reduces death risk for aggressive prostate cancer, Pg12.

Key Highlights:

• A novel combination therapy of leuprolide and enzalutamide has shown promise in reducing the risk of death in patients with high-risk, recurring prostate cancer.
• The EMBARK trial, a Phase 3 clinical trial, demonstrated that the combination therapy improved survival rates by over 40% in patients with locally advanced prostate cancer.
• Suresh Patil, a 65-year-old patient from Mumbai, experienced a significant drop in PSA levels after undergoing the combination therapy.
• The combination therapy is readily available in India, offering better survival outcomes for men with prostate cancer.
• Screening for prostate cancer is recommended for asymptomatic men starting at age 50, or earlier for those with risk factors.

Detailed Insights:

• Prostate cancer is the third most common cancer in men, often developing without noticeable symptoms in its early stages, making screening crucial for early detection and treatment.
• The combination therapy works by suppressing testosterone production (leuprolide) and blocking the remaining testosterone from fueling cancer cells (enzalutamide), effectively starving the cancer cells.
• Biochemical recurrence, indicated by rising PSA levels after initial treatment, can be a sign of cancer returning, even without physical symptoms, highlighting the need for continuous monitoring.
• The EMBARK trial involved nearly 1,000 patients across 17 countries, randomly assigned to receive either the combination therapy, leuprolide only, or enzalutamide monotherapy.
• The American Cancer Society recommends screening at age 45 for those with risk factors like family history and at age 40 for those with higher risk, such as multiple first-degree relatives with prostate cancer.
• The International Agency for Research on Cancer projects that prostate cancer incidence in India will double to approximately 71,000 new cases per year by 2040.

Key Concepts Involved:

• Prostate-Specific Antigen (PSA): A protein produced by the prostate gland; elevated levels can indicate the presence of prostate cancer.
• Biochemical Recurrence: The recurrence of cancer, indicated by rising PSA levels, after initial treatment.
• Metastasis: The spread of cancer cells from the primary site to other parts of the body.